
Armando Partida Gaytan, MD, MSc

Executive Academic CV Appendix | Medical Affairs, Specialty Care, Allergy & Clinical Immunology

Mexico City, Mexico | +52 55 3233 9342 | dr.partida.g@gmail.com | ORCID: 0000-0002-8868-9257 | Scopus ID: 56678655600

Executive Summary

Physician-scientist and medical affairs leader with a dual profile spanning specialty care pharmaceutical leadership and advanced clinical expertise in pediatric allergy, clinical immunology, primary immunodeficiencies, severe asthma, biologics, and cell and gene therapy. This appendix complements the executive CV by documenting academic formation, certifications, scientific leadership, publications, and selected scholarly outputs.

Current Positions

- Senior Medical Affairs Manager - Specialty Care, GSK Mexico.
- Founding Director - Allergy Smart Suite, Hospital San Angel Inn Satellite.
- Founding Partner - RespiCare, Hospital San Angel Inn Universidad.
- Founding Partner - Healthy Kids Polanco & Healthy Kids Queretaro.

Academic Background

Centro de Investigacion para el Acceso en Salud A.C. / DAIS - Diploma in Specialized Access to Health Institutions, 2025

Universidad Anahuac / Instituto de Alta Direccion Anahuac Business School - Finance for Directors and Non-financial Advisors, 2024

ESCP Business School - Specialty Ahead Together Programme, Executive Education Diploma, 2023

University College London, Great Ormond Street Institute of Child Health - MSc Cell and Gene Therapy, 2015-2016 - Distinction / Dean's List

Universidad Nacional Autonoma de Mexico / Instituto Nacional de Pediatria - High-specialty Fellowship in Primary Immunodeficiencies, 2013-2014

Hospital Infantil de Mexico Federico Gomez - MSc Medical Sciences, 2012-2014; Fellowship in Paediatric Allergy and Clinical Immunology, 2011-2013; Clinical Research Methods Diploma, 2009-2011; Pediatrics Residency, 2008-2011

Instituto Politecnico Nacional - Advanced Immunology Diploma, 2011

Universidad de Guadalajara - Medical Degree, 2002-2008

Certifications

- Consejo Mexicano de Certificacion en Pediatria: 2011-2016, 2017-2022, 2022-2027.
- Consejo Nacional de Inmunologia Clinica y Alergia: 2013-2018, 2018-2023, 2023-2028.
- English proficiency: IELTS 7.5 / TOEFL iBT 109.

Scientific & Professional Activities

- Associate clinical researcher at Hospital Infantil de Mexico Federico Gomez.
- Clinical researcher candidate at the National Research System (SNI - CONACyT).
- Consultant and collaborator at Fundacion Mexicana para Ninas y Ninos con Inmunodeficiencias Primarias A.C.
- Scientific committee member, Iniciativa Nadie es Menos.
- Scientific committee member, Sociedad de Especialistas en Enfermedades Raras.
- Former coeditor, Acta Pediatrica de Mexico, 2014-2019.
- Former associate researcher, Primary Immunodeficiencies Research Unit, Instituto Nacional de Pediatria.

Selected Publications & Scholarly Output

- Quantity and Quality of Dairy Product Intake and Their Relationship with Body Composition in Children and Adolescents from Mexico City. *Nutrients*, 2025.
- Two siblings with autoinflammation and combined immunodeficiency due to autosomal recessive RNF31 loss of function. *Clinical Immunology*, 2024.
- Reference values for body composition in healthy urban Mexican children and adolescents. *European Journal of Clinical Nutrition*, 2024.
- Capitulo 4. Alergia alimentaria. *Alergia, Asma e Inmunologia Pediatrica*, 2022.
- Capitulo 3. Alergia respiratoria. *Alergia, Asma e Inmunologia Pediatrica*, 2022.
- Carga economica de inmunodeficiencias primarias estimada por evidencia de vida real en el Instituto Nacional de Pediatria. *Acta Pediatrica de Mexico*, 2022.
- Chapter: Gene therapy in the treatment of primary immune deficiency diseases. In *Allergic and Immunologic Diseases*, Elsevier.
- HAX1-dependent control of mitochondrial proteostasis is essential for neutrophil granulocyte differentiation. *Journal of Clinical Investigation*, 2022.
- Severe congenital neutropenia due to G6PC3 deficiency: case series of five patients and literature review. *Scandinavian Journal of Immunology*, 2021.
- Reporte de dos casos clinicos de adolescentes con asma grave eosinofila refractaria no controlada tratados con mepolizumab a un ano de seguimiento.

- Reference values for bone mineral density in healthy Mexican children and adolescents. Bone, 2021.
- Lentiviral hematopoietic stem cell gene therapy rescues clinical phenotypes in a murine model of Pompe disease. Molecular Therapy - Methods & Clinical Development, 2020.
- Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines. World Allergy Organization Journal, 2020.
- Mepolizumab for the treatment of severe eosinophilic asthma. Revista Alergia Mexico.
- Latin American Consensus on the Supportive Management of Patients with Severe Combined Immunodeficiency. Journal of Allergy and Clinical Immunology, 2019.
- GUIMIT 2019: Guia Mexicana de Inmunoterapia. Revista Alergia Mexico, 2019.
- Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication. Frontiers in Immunology, 2017.
- Usage of human immunoglobulin in primary immunodeficiencies. Acta Pediatrica de Mexico, 2013.

Book Chapters / Guideline Contributions

- Author or co-author in chapters on severe combined immunodeficiencies, allergy and clinical immunology, food allergy, cow's milk protein allergy, and gene therapy for primary immune deficiency diseases.
- Contributor to Mexican immunotherapy guidelines and Latin American consensus documents in severe combined immunodeficiency.

Research Metrics

Research Interest Score: 169.2 | Citations: 389 | Google h-index: 10 | Google i10-index: 10.

Selected Poster Presentations

- Gene Therapy for Pompe's Disease: in vitro modelling of recombinant GAA uptake in skeletal muscle. University College London, 2016.
- Latin American Consensus on Severe Combined Immunodeficiency Treatment. IV LASID Meeting, Buenos Aires, 2015.
- Convergence of two rare X-linked diseases. European Society for Immunodeficiencies, Prague, 2014.
- Clinical and paraclinical characteristics of patients with Severe Combined Immunodeficiency: systematic literature review. UNAM Postgraduate Research Meeting, 2014.
- Selective IgM deficiency: to be or not to be. III LASID Meeting, Santiago de Chile, 2013.
- Risk factors associated with mortality in pediatric patients with hemophagocytic lymphohistiocytosis. World Allergy Congress, Cancun, 2011.
- Risk factors associated with wheezing in Mexican children: multicentric ISAAC-based survey. 2011.

Awards & Recognitions

- GSK Top Performer of the Year: 2017, 2023, 2024.
- GSK awards: 1 Gold, 6 Silver, and 4 Bronze awards across Mexico LOC, LATAM, and Emerging Markets.
- Emerging Market Talent Forum Awardee; Innovation Champion.
- ESCP First Place Business Case Challenge, Rio de Janeiro, 2023.
- UCL Dean's List and Distinction, MSc Cell and Gene Therapy.
- First place academic performance, Pediatrics Residency, Hospital Infantil de Mexico Federico Gomez.
- Multiple top academic scores in PUEM annual assessments during Pediatrics and Allergy/Clinical Immunology training.

Behavioral Competencies & Leadership Drivers

Strategic Mindset	Cultivates Innovation	Manages Ambiguity	Customer Focus
Collaborates	Balances Stakeholders	Ensures Accountability	Manages Conflict
Builds Networks	Resilience	Values Differences	Interpersonal Savvy
Situational Adaptability	Effective Communication	Self-Development	Independence
Balance	Collaboration	Challenge	

Licenses

MX GP License No. 6145519 | MX Pediatrics License No. 7876962 | MX Allergy & Immunology License No. 8070357.